## **PROVIDER OUICK POINTS** PROVIDER INFORMATION

## Note: See Quick Point QP8-20 for an update.

November 13, 2019

BlueCross BlueShield

Minnesota

## Update: Medical Drug Update for Drug Golodirsen (Vyondys 53)

Provider Quick Point <u>QP40-19</u>, that was published on May 8, 2019 is being rescinded because the Food and Drug Administration (FDA) did **not** approve the drug Golodirsen for the treatment of Duchenne Muscular Dystrophy. Therefore, Golodirsen will be removed from medical policy II-174 and the Medical Drug Evaluation Process List.